據報蘋果公司尋求今年新iPhone產量增加多達20%
《彭博通訊社》引述知情人士報道,蘋果公司(AAPL.US)已要求供應商今年生產多達9,000萬部新一代iPhone,較去年iPhone出貨量大幅增加。近年蘋果公司由發表新手機至年底的一段時間,供應量一直保持於約7,500萬部,上調今年預測表明公司預計自新型肺炎疫苗接種以來的首次發表新iPhone將釋放額外需求。
據報知情人士指,今年的新iPhone將比去年的「iPhone 12」更具增量性,強調處理器、攝像頭和顯示器的改進。蘋果計劃對目前的所有機型進行更新,包括5.4寸和6.1寸常規版本,以及6.1寸和6.7寸的Pro型號。新款手機預料將於9月發佈,比去年的10月稍早。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.